ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

ClinicalTrials.gov ID: NCT02923778

Public ClinicalTrials.gov record NCT02923778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Study identification

NCT ID
NCT02923778
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
40 participants

Conditions and interventions

Interventions

  • Biopsy Procedure Procedure
  • Biospecimen Collection Procedure
  • Magnetic Resonance Imaging Procedure
  • Radiation Therapy Radiation
  • Talimogene Laherparepvec Biological

Procedure · Radiation · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 30, 2019
Primary completion
Dec 28, 2026
Completion
Dec 28, 2026
Last update posted
May 12, 2026

2019 – 2026

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Mayo Clinic Hospital in Arizona Phoenix Arizona 85054
City of Hope Comprehensive Cancer Center Duarte California 91010
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868
Mayo Clinic in Florida Jacksonville Florida 32224-9980
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136
Moffitt Cancer Center Tampa Florida 33612
Mayo Clinic in Rochester Rochester Minnesota 55905
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141
Washington University School of Medicine St Louis Missouri 63110
Siteman Cancer Center-South County St Louis Missouri 63129
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire 03756
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232
M D Anderson Cancer Center Houston Texas 77030
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02923778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 12, 2026 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02923778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →